Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS. Chu TW, et al. Among authors: lopatin u. Gastroenterology. 2012 Apr;142(4):790-5. doi: 10.1053/j.gastro.2011.12.057. Epub 2012 Jan 13. Gastroenterology. 2012. PMID: 22248659 Clinical Trial.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Among authors: lopatin u. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Yuen MF, et al. Among authors: lopatin u. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. doi: 10.1016/S2468-1253(19)30346-2. Epub 2019 Nov 9. Lancet Gastroenterol Hepatol. 2020. PMID: 31711752 Clinical Trial.
Reduction of HBV replication prolongs the early immunological response to IFNα therapy.
Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, Bitter H, Chu T, Gruenbaum L, Ravindran P, Zhong H, Gane E, Lim SG, Chow WC, Chen PJ, Petric R, Bertoletti A, Hibberd ML. Tan AT, et al. Among authors: lopatin u. J Hepatol. 2014 Jan;60(1):54-61. doi: 10.1016/j.jhep.2013.08.020. Epub 2013 Aug 29. J Hepatol. 2014. PMID: 23994382 Clinical Trial.
Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.
de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW. de Niet A, et al. Among authors: lopatin u. Scand J Gastroenterol. 2012 Apr;47(4):475-81. doi: 10.3109/00365521.2011.648952. Epub 2012 Jan 23. Scand J Gastroenterol. 2012. PMID: 22263608 Clinical Trial.
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Sulkowski MS, et al. Among authors: lopatin u. J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11. J Hepatol. 2022. PMID: 35697332 Free article. Clinical Trial.
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Yuen MF, et al. Among authors: lopatin u. J Hepatol. 2022 Sep;77(3):642-652. doi: 10.1016/j.jhep.2022.04.005. Epub 2022 Apr 20. J Hepatol. 2022. PMID: 35460726 Free article. Clinical Trial.
Transcriptomic analysis of the woodchuck model of chronic hepatitis B.
Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, Ma H, Klumpp K, Menne S. Fletcher SP, et al. Among authors: lopatin u. Hepatology. 2012 Sep;56(3):820-30. doi: 10.1002/hep.25730. Epub 2012 Jul 12. Hepatology. 2012. PMID: 22431061 Free PMC article.
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW. Jansen L, et al. Among authors: lopatin u. J Hepatol. 2014 Oct;61(4):730-7. doi: 10.1016/j.jhep.2014.05.004. Epub 2014 May 10. J Hepatol. 2014. PMID: 24824278
Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
Jansen L, Welkers MRA, van Dort KA, Takkenberg RB, Lopatin U, Zaaijer HL, de Jong MD, Reesink HW, Kootstra NA. Jansen L, et al. Among authors: lopatin u. Antiviral Res. 2017 Sep;145:87-95. doi: 10.1016/j.antiviral.2017.07.013. Epub 2017 Jul 25. Antiviral Res. 2017. PMID: 28754258 Free article.
29 results